Latest

3 stories

Hide weekly roundups

Monday, August 31

Edgewise Therapeutics registers Phase 2 EQUINOX-HFpEF study of EDG-15400

Trial updateEDG-15400 Edgewise Therapeutics, Inc.

Thursday, August 6

Quarterly updateEDG-7500 Edgewise Therapeutics, Inc.

Edgewise reports Q2 2026 results, positive Phase 2 HCM data and closed Servier sale

Edgewise plans a Phase 3 HCM trial in Q4 2026 after positive EDG-7500 data, and booked $1.55 billion upfront from its muscular dystrophy business sale to Servier.

SEC filing

Monday, July 13

M&AEDG-7500 Edgewise Therapeutics, Inc.sevasemten

Edgewise completes sevasemten sale to Servier, sharpens cardiovascular focus

The July 10, 2026 closing brings Edgewise $1.55 billion upfront plus up to $1.1 billion in milestones, funding EDG-7500 through potential approval.

SEC filing